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Tracing clonal development and cell lineages in
human tumours
P.J. Fialkow
Department ofMedicine, University of Washington,
Seattle, WA 98195, USA.
Clonal development of neoplasms and hierarchal
stem cell relationships can be studied conveniently
in people who have two genetically distinct types of
cells. Especially useful for this purpose is the
cellular mosaicism in women heterozygous for the
X-chromosome-linked glucose-6-phosphate de-
hydrogenase (G6PD). Because the G6PD locus
undergoes X-chromosome inactivation, only one of
the two G6PD genes is active in each somatic cell.
Therefore, women heterozygous for the usual B
gene (GdB) and a variant such as GdAhave two cell
populations - one synthesizing B-type G6PD and
the other, A-type enzyme. Tumours with a single-
cell (clonal) development exhibit only one type of
G6PD, but those arising from many cells may show
both B and A enzymes. Only one type of G6PD
was detected in granulocytes, red cells and platelets
from 30 females heterozygous for G6PD who had
chronic myelocytic leukaemia (CML), indicating
that this disorder involves multipotent marrow stem
cells and that it develops clonally. Detailed studies
with G6PD indicate that B-lymphoid and perhaps
T-lymphoid cells arise from the stem cell involved
by the leukaemia. Acute myeloid leukaemia is
heterogeneous with respect to the pattern of stem
cell involvement and the nature of remission. In
some patients, the disease involves stem cells with
multipotent differentiative expression, whereas in
others it involves progenitors with differentiative
expression restricted to the granulocytic pathway.
G6PD and chromosome studies also suggest that
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the myeloid leukaemias have a multistep
pathogenesis with clonal proliferation of marrow
cells preceding acquisition of distinctive
chromosomal abnormalities. Evidence for clonal
development has also been adduced for many but
not all of the other human tumours studied with
G6PD.
Investigations of a stem cell model for human cancer;
cell-renewal, differentiation and oncogene expression
in human ovarian cancer
R.N. Buick
Ontario Cancer Institute and Department ofMedical
Biophysics, University of Toronto, Toronto, Ontario,
Canada, M4X 1K9
We have investigated the possibility of stem cell
renewal and differentiation in human malignant
epithelium. This has been performed both at the
theoretical level and practically by assessing cellular
features of human ovarian carcinomas. Cells
derived from this type of tumour are heterogeneous
with respect to a number of functional and
phenotypic markers (labelling index, clonogenicity
in tissue culture, histochemically-marked differen-
tiation, cell surface expression of ovarian tumour-
associated antigens). The fact that physical
properties of the cells also change with differen-
tiation has allowed the fractionation of tumour
cell populations (on the basis of density and/or
volume) and the putative ordering of differen-
tiation markers. We have used these techniques
to study the process of tumour progression in
one patient. A model has evolved ofa clonal differen-
tiation hierarchy based on analysis of individual cell
proliferative potential and cell differentiation state.
During a screen of ovarian carcinoma samples
for activation of protoncogenes, we have identified
a single case of ovarian carcinoma in which there is
an amplification (-25-fold) and over-expression of
the protoncogene c-K-ras. Diploid cells purified
© The Macmillan Press Ltd., 1985582 BACR/RSM ABSTRACTS
from the tumour are not amplified. Five
consecutive ascitic tumour samples, harvested from
the patient over a nine month period of clinical
progression, showed no change in level of c-K-ras
amplification. In this patient therefore, an
amplification of c-K-ras has occurred as a somatic
mutation; but the over-expression of the gene does
not relate to the process of clinical progression.
Germ cell tumours of the testicle as a model of
clonal evolution in man
R.T.D. Oliver
Department of Urology, The London Hospital,
Whitechapel El JBB, UK.
In recent years the concept of malignant Teratomas
arising from embryonic nests has been less favoured
as an explanation for their origin. A common germ
cell origin of all malignant Teratomas and
Seminomas from transformed spermatogonia as
proposed by Pierce & Abel has become the more
acceptable hypothesis though there is still some
dispute about the interrelation of the different
tumour types, most regarding Seminoma as separate
entity from the other major tumour types which are
grouped together collectively as Non-Seminomas.
This paper will review data from clinical,
epidemiological, histopathological and tumour
marker studies in support of the hypothesis that
Seminoma is in fact an intermediate stage in the
clonal evolution of the germ cell from normal
spermatogonia to malignant germ cell through
which all patients with germ cell tumours initially
pass, the final phenotype of malignancy expressed
being dependant on the rate of evolution following
initiation.
Dihydrofolate reductase gene amplification in
somatic cells
R.T. Schimke
Department ofBiological Sciences, Stanford
University, Stanford, CA 94305, USA.
Gene amplification in cultured mammalian cells has
now been reported for at least 10 different genes.
Amplification is observed with step-wise selection,
and the amplified genes can occur on one or
more chromosomes, or as self-replicating extra-
chromosomal elements. Evidence will be presented
to support the concept that amplification occurs as
a result of overreplication of the genome in a single
cell cycle, followed by recombination events to
generate chromosomal or extrachromosomal genes.
A variety of treatments, including transient in-
hibition of DNA synthesis, treatment of cells with
UV or carcinogens, or treatment of cells with
elevated temperatures, results in overreplication of
DNA. The overreplication of DNA involves more
than a single gene, and results in a number of
chromosomal changes, including fragmented
chromosomes, increased sister chromatid exchange,
dicentric chromosomes, and varying degrees of
endoreduplicated chromosomes. The hypothesis will
be advanced that major chromosomal rearrange-
ments, including generation of aneuploidy results
from overreplication of DNA followed by various
types of recombination events.
Tumour development in experimental animal bladder
cancer models
R.M. Hicks
School ofPathology, Middlesex Hospital Medical
School, Riding House Street, London WIP 7LD,
UK.
Bladder cancer is a disease of multifocal primaries
with a 70% recurrence rate within 5 years. Eighty
per cent of first patients present with benign, well-
differentiated papillary lesions but it can also occur
as flat, poorly-differentiated invasive carcinoma
arising from diffuse carcinoma in situ . Previously,
using experimental rat models, we demonstrated the
development of the papillary lesions to be stepwise
through a multistage process analogous to initiation
and promotion in the skin. By contrast, the
response of the B6D2F1 mouse to the bladder
carcinogen BBN was less uniform and indicated
that not all invasive bladder lessions necessarily
progress via the same mechanism. The response of
the experimental bladder cancer models to
treatment with retinoids (analogues of vitamin A)
has now been studied. In the rat model, certain
retinoids delay the latent period before tumour
growth commences, thus reducing the time-related
prevalence of bladder cancer and increasing the
survival of the animals. This was predictable for
tumours which develop via initiation and
promotion, for retinoids are known to inhibit stage
2 promotion (clonal expansion of preneoplastic
cells) in vitro. In the mouse model also retinoids
delay the development of the majority of invasive
carcinomas, but a small minority of rapidly
developing, aggresively invasive cancers appear to
be unaffected by this treatment. The development
of such lesions may or may not be stepwise, but it
does not appear to involve "promotion" in the
same way as does the development of papillary
carcinomas. These observations have clinical
implications for the use of retinoids as chemo-
preventive agents in the management of bladder
cancer patients.BACR/RSM ABSTRACTS 583
Oncogene activation and multistage carcinogenesis in
mouse skin
A. Balmain, M. Quintanilla, M. Ramsden &
K. Brown
The Beatson Institutefor Cancer Research, Garscube
Estate, Switchback Road, Glasgow G61 IBD, UK.
The activation of oncogenes by mutation,
translocation or amplification has been implicated
in the development of a variety of both human and
animal tumours. However, carcinogenesis is known
to be a multistage process, and the precise step at
which particular oncogenes become activated is
unclear. We have been using a mouse skin model
system to study the stage-specific activation of ras
genes both in vivo and in vitro. Our results suggest
that activation of ras genes in vivo occurs at a
relatively early stage, since chemically induced
benign papillomas have an activated Harvey-ras
gene which can transform NIH/3T3 cells in a
transfection assay. The method of activation of the
gene does not appear to be identical in all tumours,
since we have detected at least three different forms
of the Harvey-ras p21 in a series of tumours
induced by treatment with dimethylbenzanthracene.
Differences between the stage-specific activation of
ras genes in vivo and in vitro will be discussed.
Clonal heterogeneity within mouse mammary
tumours
G.H. Heppner
Michigan Cancer Foundation, Detroit, Michigan,
48201, USA.
Clonal heterogeneity is an accepted feature of
neoplasia and is considered to be the basis of
neoplastic progression. My colleagues and I have
developed a model system to examine the role of
heterogeneity in tumour behavior. Our system
consists of a series of subpopulation lines that were
derived from the same, spontaneously arising strain
BALB/cfC3H mouse mammary tumour. These
tumour lines differ in characteristics such as
immunogenicity, drug sensitivity, and ability to
metastasize. This presentation will focus on two
aspects of our work: (1) the ability of clonal
subpopulations to interact so as to alter their
behavioural characteristics. Subpopulation inter-
actions impose a societal aspect to clonal
heterogeneity. The behavior of a tumour cannot be
deduced from knowledge of the individual
characteristics of its component clones. (2) The
ability of clonal subpopulations to invoke host
infiltrates that differ in the distribution of in-
flammatory cell subtypes. I will discuss how this
inflammatory cell heterogeneity may impact on the
continuing development of tumour cell hetero-
geneity with emphasis on the release of mutagens
by tumour-associated macrophages. My overall
theme is the interplay between tumour cell hetero-
geneity and host cell heterogeneity in the
development of the tumour ecosystem.
Biological determination of homing patterns of
metastasis
I.R. Hart
Imperial Cancer Research Fund Laboratories,
Lincoln's Inn Fields, London, WC2A 3PX, UK.
Malignant tumours of defined histologic type
frequently exhibit distinct patterns of metastatic
development with non-random involvement of
specific organs. Simple mechanical entrapment of
disseminating neoplastic cells determined by the
anatomical location of the primary tumour, true
organ trophism dependent on cell arrest mediated
by specific recognition and organ-determined
modulation of cancer cell growth all have been
proposed as mechanisms responsible for the
specificity of secondary tumour development. These
mechanisms have been investigated experimentally
using two murine tumours of spontaneous origin;
the B16 melanoma which metastasizes preferentially
to the lungs and the M5076 reticulum cell sarcoma
of macrophage origin which metastasizes almost
exclusively to the liver and spleen. Clonal analysis
of heterogeneous tumour cell populations has
revealed diversity for the phenotype of site-specific
metastasis. The relationship of these results to the
clonal evolution of tumours and possible future
approaches to the problem of site specific
metastasis will be discussed.
Role of oncogene activation in the multistep
malignant transformation of mammalian cells in
culture
A.S.C. Medcalf & R.F. Newbold
Institute ofCancer Research, Fulham Road, London,
SW3 6JB, UK.
Carcinogenesis is a multistage process in both
humans and carcinogen-treated laboratory rodents.
Consequently, cancer cells are likely to contain a
number of superimposed heritable alterations which
have accumulated over a protracted period of time
during the evolution of the tumour. The recent
development of improved cell culture models for
carcinogenesis, together with techniques for DNA-
mediated gene transfer has facilitated studies of the
genetic basis of the important rate-limiting steps.
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fibroblasts we have been able to identify two
distinct phases in the process of carcinogen-induced
malignant transformation. These are (i) the
appearance of rate variant cells with an infinite
capacity for self-renewal, followed by (ii)
progression by clonal selection, of the resulting
immortal cell lines to a state of anchorage
independence, serum growth-factor independence
and tumorigenicity. Activated human oncogenes of
the ras family are capable on transfection of
accomplishing the latter step, although they may
not actively play a major role in transformation
induced by carcinogens in this system. Moreover,
the ras oncogenes do not possess any capacity for
immortalisation suggesting that they are stage-
specific with respect to their transforming
properties.
New developments in breast cancer research and
management
U. Veronesi
Istituto Nazionale Tumori, Via Venezian, 1, 20133
Milano, Itai',
Breast cancer management is at the centre of
innumerable debates and is a reason for lively
controversy. The lack of consensus is not only due
to the different opinions of investigators claiming
equally good results with different treatments, or to
difficulty of digesting the welter of data from
hundreds of clinical studies, but has deeper roots
concerning unsolved concepts on the biology of
breast cancer. It appears, therefore, reasonable to
plan a research programme directed at a better
understanding of the natural history of breast
cancer and on the other hand to organize, with
sophisticated methodology, appropriate clinical
trials in order to give a rational answer to the many
questions on the more adequate types of treatment.
In the last 10 years surgery, radiotherapy,
chemotherapy and endocrine therapy have
drastically changed their respective rules in the
management of cancer of the breast and its regional
and distant metastases. Less mutilating surgical
techniques, more rational utilization of radiation,
anticipated use of chemotherapy and more specific
application of endocrine treatment are the main
aspects of the new course.
Abstracts of members' proffered papers
Evidence that N-(deoxyguanosin-8-yl)-1-aminopyrene
is a major DNA adduct in female rats administered
1-nitropyrene
C.A. Stanton', F.L. Chow', D.L. Philips2,
P. Grover2, R.C. Garner1 & C.N. Martin'
1Cancer Research Unit, University of York,
Heslington, York YOJ 5DD. 2Chester Beatty
Research Institute, Fulham Road, London SW3 6JB,
U.K.
[3H]l-nitropyrene (lNP) (5mgkg-1) was adminis-
tered by i.p. injection to female rats. Animals
were killed 24h later and DNA was isolated from
kidney, liver and mammary gland. The adducted
DNA was enzymically hydrolysed and analysed by
reverse-phase hplc. One major adduct was detected
in each of the three organs. Enzymic hydrolysates
of DNA which had been reacted in vitro with INP
in the presence of xanthine oxidase, were similarly
analysed by hplc. One major adduct was obtained
which had the same retention time as the in vivo
product. Confirmatory evidence that the in vivo and
in vitro adducts were structurally similar was
obtained from the determination of the pH-
dependent solvent partitioning profiles. Further,
treatment of both the in vivo and in vitro adducts
with sodium hydroxide resulted in the formation of
a more polar product which eluted earlier on hplc.
This behaviour is not inconsistent with scission of
the imidazole ring of deoxyguanosine. The major
DNA adduct formed in vitro following xanthine
oxidase reduction of 1-nitropyrene has previously
been identified by others as N-(deoxyguanosin-8-
yl)-l-aminopyrene. The present data suggests that
the in vivo 1-nitropyrene/DNA adduct isolated has
a similar structure.
The effect of oesophageal carcinogenic nitrosamines
on the 06-alkylguanine-DNA alkyl transferase in
rat oesophagus and liver
V.M. Craddock
MRC Toxicology Unit, Woodmansterne Road,
Carshalton, Surrey, UK.
Although the incidence of oesophageal cancer in
women in Britain is the highest in Europe, possible
causes have barely been considered. The only
carcinogenes known which have a potent highly
selective action of the oesophagus are certain
nitrosamines. Their mechanism of action is there-
fore of interest. The potency of nitrosamines is
reputed to be related to the time for which 06_
alkylguanine (06AG) formed as a result of nitro-BACR/RSM ABSTRACTS 585
samine treatment persists in cellular DNA. The
alkyl group of this adduct is removed from DNA
by O6AG-DNA alkyl transferase, the protein acting
as a stoichiometric alkyl group acceptor (AAP). A
level of alkylation of DNA high in relation to the
AAP content of the cell can completely alkylate the
available AAP, thereby slowing down repair, and
increasing the chance of malignancy. Therefore the
ability of a nitrosamine to deplete the AAP should
give a more reliable and easier to measure estimate
of carcinogenic potency for the organ concerned
than does the level of alkylation of DNA.
To determine whether this concept applies to the
oesophagus, the ability of relevant nitrosamines to
deplete oesophageal and liver AAP was studied.
Extracts of these organs from treated animals were
tested for their ability to remove 06AG on
incubation with previously alkylated DNA. Methyl-
benzylnitrosamine (oesophageal specific), diethyl-
nitrosamine (carcinogenic for oesophagus and
liver), and dimethylnitrosamine (carcinogenic for
liver but not for oesophagus) depleted liver and
oesophageal AAP, and dose response studies
revealed a selective action on the target organs.
Methylphenylnitrosamine (MPN, oesophageal
specific) did not deplete but induced AAP in liver
and possibly in oesophagus. This result supports
the evidence that MPN does not alkylate DNA.
The higher levels of AAP found in human organs
may not protect man against the majority of
environmental nitrosamines.
The catalysis of N-nitrosamine formation by clinical
isolates of bacteria
S.A. Leach', B. Challis2, A.R. Cook', M.J. Hill' &
M.H. Thompson'
IPHLS Centrefor Applied Microbiology and
Research, Bacterial Metabolism Research Lab.,
Porton Down, Salisbury, SP4 OJG, 2Imperial College
ofScience and Technology, Department of
Chemistry, London SW7 2AY, UK.
The promotion of N-nitroso compound formation
at neutral pH by bacteria infecting certain bodily
sites (stomach, urinary bladder) may account for
the increased incidence of carcinogenesis observed
in certain population groups. N-nitrosamines are
formed in aqueous systems by an acid catalysed
reaction between nitrite and secondary amine (pH
optimum 2-3), the reaction rate decreasing rapidly
as the pH approaches neutrality. Much early work
was prone to artefacts caused by inadequate
controls and lack of specific detection methods. In
this work bacterial cells were added to a reaction
mixture of secondary amine and nitrite in
phosphate buffer at neutral pH. Any nitrosamine
was extracted and analysed by GC-TEA (Thermal
Energy Analyser-specific for nitrosamines). Experi-
ments of short duration (<1 h) in the absence of
media prevented artefacts due to acidification of the
reaction mix. Of 8 clinical isolates of Escherichia
coli, half were able to nitrosate morpholine. Heat
killed cells, cell suspension supernates and sonicated
cells all ceased to show any activity. Of 5 clinical
gastric isolates none showed any ability to
nitrosate. Lineweaver-Burk plots of the kinetic data
give good linear relationships up to high concen-
trations of both substrates, when substrate
inhibition is observed. With each of the amines
used (morpholine, piperidine N-methylpiperazine) a
distinct pH optimum is observed in the range 6-8,
in contrast to the acid catalysed reaction. The
kinetic and pH optima data all support the
involvement of some bacterial enzyme (system) in
this reaction. Further work using bacteria of gastric
and urinary origin in continuous culture models of
the infected stomach and bladder will now be used
to better assess the clinical significance of the
bacterially catalysed reaction.
Human papillomavirus 6 DNA and cervical cancer:
Prevalence in cervical scrapes
C. Wickenden', Malcolm' & D.V. Coleman2
2Dept ofPathology, St Mary's Hospital Medical
School, London, W2 IPG, 2Department of
Biochemistry, Charing Cross Hospital, London,
W6 8RF, UK.
The object of this study was to develop a non-
invasive method for studying HPV infection in the
uterine cervix and to study the link between HPV
infection and cervical oncogenesis. Cervical
scrapings were obtained from 5 groups of women:
(i) well women, (ii) women with CIN, (iii) women
successfully treated for CIN, (iv) VD clinic women
free from genital warts, and (v) VD clinic women
with genital warts.
DNA purified from these samples was blotted
onto nylon filters and hybridised sequentially to
HPV type 6 DNA and to a repetitive sequence
associated with the globin gene, both cloned into
the pBR 322 plasmid and labelled with 32P by nick
translation (Rigby et al., 1975).
Results are summarised below. The percent
positive for HPV 6 DNA is calculated as a propor-
tion of the cases positive for the repeat probe.
Group
(i)
(ii)
(iii)
(iv)
(v)
Total
22
20
23
22
6
+ve Repeat
18
14
20
19
4
+ve HPV
0
2
2
2
2
HPV/
Repeat
0%
14%
10%
10.5%
50%586 BACR/RSM ABSTRACTS
These findings indicate that HPV infection may
be found in normal appearing cervices and these
women possibly represent a hitherto unrecognised
high risk group for CIN.
Loss of chromosome and enzyme markers in cultures
from testicular tumours
J.M. Parrington, L.F. West & S. Povey
MRC Human Biochemical Genetics Unit, the Galton
Laboratory, University College London, Wolfson
House, 4 Stephenson Way, London NW] 2HE, UK.
In order to identify chromosome changes which
may be important in the development of testicular
tumours, aneuploid cell lines were established from
3 teratomas and one mixed teratoma/seminoma.
These were G banded, and typed for both C and Q
band heteromorphic markers and selected electro-
phoretic enzyme variants, and compared with
karyotypically normal material from the same
patients.
The 6 aneuploid cell lines all had a modal
chromosome number between 55 and 60 and
certain chromosome changes in common: re-
arrangements of chromosome No. 1, trisomy Nos.
17 and 12, and several small metacentric markers.
C band markers on No. 1 were heteromorphic in
diploid cells from all 4 patients. In "tumour" cell
lines from the 3 teratoma patients an extra
rearranged No. 1 was present involving duplication
of Jq. The intact No. l's in these cell lines were
homomorphic for the C band marker suggesting
duplication of one No. 1. In the other, only the
long arm is duplicated and the short arm deleted.
Enzyme markers on lp have so far been
informative in two cases with loss of one PGM1
allele in one case and FUCA allele in the other.
Analysis of polymorphisms at other sites is in
progress.
Clearly a non random pattern of chromosome
losses and gains exists in these cell lines similar to
that observed in direct preparations from tumour
material (Atkin & Baker (1983) Cancer Genet.
Cytogenet., 10, 199). Loss of specific wild type genes
by gross chromosome change mat be important in
the aetiology of testicular tumours, as it appears to
be in retinoblastoma (Cavenee et al. (1984) Nature,
305, 799) and Wilm's tumour (Koufos et al. (1984)
Nature, 309, 170).
Enhanced metastatic capacity of mouse mammary
carcinoma cells transfected with H-RAS
S.A. Eccles, C. Marshall, K. Vousden & H. Purvies
Institute ofCancer Research, Sutton and London,
UK.
MTI Clone 5/7 retains many of the properties of its
parent mouse mammary tumour: in vivo it produces
well-differentiated adenocarcinomas from which
spontaneous metastasis is rare (<10% of hosts),
and confined to lungs. We wished to examine
whether genetic manipulation of these cells could
alter their metastatic phenotype. Cells were
transfected with a neomycin resistance gene alone,
or in combination with an H-ras gene using
plasmidcs pSV2-NEO and pSV2-NEO-EJ respec-
tively. The selection and cloning of transfected cells
was carried out in 1 mgml 1 G418. Neither 3 NEO
clones nor 3 EJ clones differed significantly from
the parental cell line in their tumorigenicity and
growth rates s.c., or in their lung colonisation
potential in syngeneic mice. However, the incidence
of spontaneous metastases was increased
significantly to 40%, 42% and 66% (NEO clones)
or 92%, 100% and 100% (EJ clones), and most
major tissues were now involved including brain,
bone, muscle and endocrine glands. These results
show that transfection with pSV2 vectors can
influence metastasis in the absence of detectable
effects on tumorigenicity, and that the integration
of transforming genes can further potentiate
tumour progression.
Organ-specific effects of metastatic growth studied
in vitro
D. Darling, E. Horak & D. Tarin
Nuffield Department ofPathology, University of
Oxford, John Radcliffe Hospital, Oxford OX3 9DU,
UK.
Although the cells from disseminating malignant
tumours rapidly arrive in all organs, they only grow
in some sites, and success or failure in forming
metastatic deposits is dependent upon interaction
between properties of the tumour cells and the
microenvironment. In the present study the
influence of microenvironmental conditions of
specific organs upon tumour cell survival and
behaviour was investigated in tissue culture using
spontaneous mouse mammary carcinomas. In co-
cultures, some organs (lung, ovary) encourage the
survival and the attachment of the tumour cells,
while others (liver, thyroid) accelerate the process
of cell destruction. These effects are exerted by
soluble mediators which can be transferred with
cell-free organ-conditioned medium from one
culture to another and are significantly more
pronounced in cells from the same animal species.
The "stimulatory" influence is rather a preservation
of the tumour cells, than a stimulation of their
multiplication, as suggested by 125IUdR-uptake
studies. It is known that, after in vivo inoculation,
these mammary tumours develop metastases mainly
in the lungs, and occasionally in the kidneys orBACR/RSM ABSTRACTS 587
ovaries, and the "encouraging" influences of these
same organs in vitro are thus in good agreement
with the in vivo observations. The findings also
endorse the hypothesis that certain normal organs
can suppress the formation of metastases even
though cells from the same tumour have formed
them elsewhere.
Effects of the concentrations of oxygen in the
ambient atmosphere on growth in vitro of rodent
cancer cells
R. Clarke, P.V. Senior, K. Moore & P. Alexander
CRC Dept. ofMedical Oncology, University of
Southampton, Southampton General Hospital, UK.
The concentration of oxygen encountered by cancer
cells arrested in capillary beds is much higher than
that in the extracellular fluid which is the normal
milieu in which they grow in vivo. This raises the
possibility that oxygen toxicity contributes to the
high rate of intravascular destruction of cancer cells
that have been shed into the circulation. We have
compared the growth in vitro of cancer cells taken
directly from a number of rodent tumours in
atmospheres containing 5% and 20% oxygen.
Growth was assessed by measurement of increase in
cell numbers in microwells (the proliferation assay)
and by the fraction of cells forming colonies in soft
agar (the clonogenic assay). With most of the
tumours studied growth in both assays was greater
in 5% than in 20% oxygen. This oxygen effect was
not observed with two carcinomas tested, but these
cells could be rendered sensitive to the toxic effects
of 20% oxygen by depletion of cellular glutathione
by treatment with the glutathione synthesis
inhibitor, buthionine sulphoximine.
The reverse phenomenon (i.e. induction of
resistance to 20% oxygen) was seen when oxygen
sensitive tumour cells had been established in cell
culture for a number of passages. So far we have
conflicting data on the permanence of this change
following re-establishment of the cultured cells as a
tumour in vivo and cannot decide whether it is an
adaptive response of the cells or whether oxygen
resistant variants, which have no proliferative
advantage in vivo were selected in vitro.
Preferential adrenal growth from bloodborne tumour
cell emboli
P. Murphy1, I. Taylor' & P. Alexander2
'Dept. ofSurgery and 2CRC Dept. ofMedical
Oncology, University ofSouthampton, Southampton
General Hospital, UK.
Human autopsy data shows that for carcinoma
cells that have gained access to the arterial
circulation the adrenal is a frequent site for
metastasis in spite of the small proportion of
cardiac output received by this organ. In
experimental animals the same has been observed
following direct inoculation of a variety of cancer
cells into the left ventricle. We have studied the
metastatic pattern of 3 syngeneic rat rumours
(sarcoma, carcinoma and hepatoma) injected into
the left ventricle via carotid cannulae. The fate of
inoculated cells was determined with 125IUdR-
labelled cells and the cardiac output distribution by
injecting radioactive microspheres.
The adrenal was the commonest site for
metastasis for all 3 tumours (80 of 86 rats) despite
receiving only 0.4% of cardiac output (n= 12) and
trapping only 0.2% of tumour cells (n= 11). In
contrast the kidney developed metastasis rarely (1
of 86 rats) despite receiving 13.4% of cardiac
output and trapping 9.3% of cells. Injection of a
cell dose such that a predicted 100 sarcoma cells
arrested in the adrenals produced metastasis in 10
out of 10 rats and a predicted 10-30 cells produced
metastases in 5 of 7 rats whereas more than 45,000
cells arrested in the kidney failed to produce
metastasis in 18 rats.
Metastatic pattern did not correlate with
vascularity/gram and autoradiography demonstrated
that the tumour cells were trapped at the arterial end
ofthecapillaries in both kidney and adrenal. Pharma-
cological manipulations of adrenal function altered
the metastatic pattern.
We conclude that local biochemical factors may
be responsible for preferential growth in adrenals.
Flow cytometric analysis of heterogeneity in
colorectal cancer
N. Armitage', R.A. Robins2, L. Durrant2, R.W.
Baldwin2 & J.D. Hardcastlel
'Department ofSurgery and 2Cancer Research
Campaign Laboratories, University Hospital,
Queen's Medical Centre, Nottingham NG7 2UH,
UK.
In considering monoclonal antibodies for targeting
antitumour agents the heterogeneity of antigen
expression between cells in an individual tumour is
of importance. This heterogeneity was examined in
colorectal cancers and related to DNA content
abnormalities. Sixteen colorectal cancers were dis-
aggregated to yield viable tumour cell suspensions.
These were tested by indirect immunofluorescence
with a panel of antitumour monoclonal antibodies
- anticolonic adenoma (C14), antiCEA/NCA (C24)
and antiCEA (LI1/285) and normal mouse
immunoglobulin (NMI). The flow cytometric
measurement of fluorescence was analysed and cells
subdivided arbitrarily into those binding antibody at
different degrees. The percentage of the total cells
falling into each "band" was calculated (see Table I).588 BACR/RSM ABSTRACTS
Table I Number of tumours with >20% of cells in each "band"
Antibody Nil Moderate Good Strong Fluorescence
Binding (0-200) (200-1000) (1000-2000) (>2000) units
NMI 16 0 0 0
C14 16 9 1 1
C24 (14 tumours) 11 6 1 3
LIl/285 15 11 2 2
In six cancers those cells positive for C24 were
sorted from those negative and the DNA content
measured. The C24 positive cells contained a higher
proportion of aneuploid cells - median 80% (12-
89%) than the C24 negative cells median 26% (12-
46%) (U=4.5, P=0.01). Tumour cells show
considerable variation in antigen expression and for
effective drug targeting a combination of antibodies
may be required. However the more aggressive
aneuploid cells are more likely to bind antibody.
Flow cytometric analysis of lymphocyte
subpopulations during tumour growth in rats - A fall
in helper T lymphocytes in the first 7 days after
inoculation
T.W.J. Lennard, B.K. Shenton, M. White,
G. Proud & R.M.R. Taylor
Department ofSurgery, University ofNewcastle
upon Tyne, UK.
Lymphocyte subpopulations in the peripheral blood
of WAB rats during the growth of an MC7
sarcoma have been studied using a panel of
monoclonal antibodies to Pan T (W3/13) helper
(W3/25) and suppressor (OX8) lymphocytes.
Analysis was by flow cytometry (FACS 420,
Becton-Dickinson, California) using right angle
scatter to exclude monocytes, macrophages,
polymorphs and large granular lymphocytes (NK
cells) (Ritchie et al. J. Immunol. Meth. (in press)).
Thirty syngeneic female WAB rats were injected
with 106 viable cells from a single MC7 sarcoma.
Twelve animals with saline injection acted as
controls. Animals were venesected (9am) at 3, 5, 7,
10, 12 and 14 days after injection. A fall in
W3/25 +ve cells was found at Day 3 and Day 7
compared to controls, and at Day 14 a rise in
W3/25 + ve and fall in OX8 +ve cells was found
(see Table II).
Table II (Median % +ve lymphocytes in peripheral
blood)
W3/13 W3/25 OX8
Control 86.8 60.9 38.7
Day 3 91.7 56.2a 42.9
Day 7 80.2 49a 39.3
Day 14 90.6 69.la 23.8b
P= <0.05
bp= <0.01 Mann Whitney u test
Early tumour growth is associated with changes in
circulating immunoregulatory lymphocyte sub-
populations and these occur in helper T lympho-
cytes.
Tumour cells possess guanidinobenzoatase. Location
of cells with fluorescent inhibitors of this enzyme
F.S. Steven
Dept. ofBiochemistry, University ofManchester,
Manchester M13 9PT, UK.
The aims have been to (1) design fluorescent probes
for the active centre of a proteolytic enzyme which
tumour cells possess, and (2) employ these probes
to locate tumour cells in sections of pathological
tissue. The unusual enzyme, guanidinobenzoatase,
has been shown to be associated with tumour cells
and has been isolated by affinity chromatography
on N-substituted guanidino-Sepharoses. Kinetic
studies have enabled the selection of competitive
inhibitors of guanidinobenzoatase. Fluorescent
inhibitors (e.g. dansyl-homoarginine and 9-amino
acridine) were shown to bind the active centre of
guanidinobenzoatase. These compounds acted as
fluorescent probes which can be employed to locate
cells possessing this enzyme in formalin-fixed, wax-
embedded sections. The probes did not bind to
other cell-associated neutral proteases. It was
observed that pure guanidinobenzoatase cleavesBACR/RSM ABSTRACTS 589
fibronectin and may be concerned with the
ability of tumour cells to migrate or detach. This
enzyme is also associated with the lymphocytes in
the germinal centres of lymph nodes and developing
spermatozoa in the seminiferous tubules.
Cultured normal rat liver cells lack guanidi-
nobenzoatase but transformed liver cells possess
this enzyme and can be located with 9-amino
acridine. It seems likely that one of the chemical
events in tumourogensis involves the synthesis of
guanidinobenzoatase.
Circulating leukocyte subpopulations and their
functions in benign and malignant disease
E.G. Allen, T.W.J. Lennard, B.K. Shenton,
M. White, R.K. Jordan, G. Proud &
R.M.R. Taylor
Departments of Surgery and Anatomy, University of
Newcastle Upon Tyne, UK.
Circulating leukocyte populations were investigated
using monoclonal antibodies and flow cytometry
(FACS 420) in tumour bearing patients (TBP) with
concurrent functional assays (mixed leukocyte
culture, MLC).
Table Mean % positive cells+s.e. (n)
Normals Benign TBP
Leu 4 73.5+0.7 (127) 74.4+ 1.6 (52) 68.4+2.2(52)
Leu 3 44.1 + 1.0 (119) 47.6+ 1.9 (39) 45.7+2.1 (52)
Leu 2 26.7+0.8 (121) 28.3+1.7 (39) 26.5+1.5 (53)
Leu I 1 18.2+0.9 (50) 15.4+ 1.0 (33) 18.0+ 1.4 (45)
In 14 of these benign, 17 TBP and 22 "normal"
humans, MLC was performed from the same blood
sample. Mean stimulation indices (SI) did not differ
between the three groups in stimulator: responder
culture ratios of 1:2, 1:1 and 1:0.5. There was no
significant correlation between the % positive Leu 3
cells and the mean SI except in the benign group in
MLC ratios 1:2 and 1:0.5 (P<0.05).
We conclude that the MLC correlates poorly
with the % of Leu 3 positive cells.
Chemotherapy in advanced metastatic seminoma of
the testis
G. Read & P.M. Wilkinson
Departments of Radiotherapy and Clinical
Pharmacology, Christie Hospital and Holt Radium
Institute, Manchester, M20 9BX, UK.
Although survival in stage I/IIA seminoma of the
testis is excellent (96%) with radiotherapy alone (G.
Read et al. (1983) Clin. Radiol. 34, 469) other
stages are less satisfactory: IIB 61% III 51% and
IV 13% and treatment for supradiaphragmatic
relapse is poor (G. Read (1981) Clin Radiol. 31,
349). Since 1980, 31 patients have received
combination chemotherapy for metastatic testicular
or retroperitoneal seminoma, 7 at presentation (2
IIB, 2 III and 3 IV) and 24 at relapse (5 IIB, 9 III
and 10 IV). Combinations were as follows VB 1,
PVB 6, PVEB 1, VEP 11 and CEV 12. CR was
obtained in 21, PR 7 and 2 progressive (1 NA).
19/31 (61%) are alive and disease free (minimum
FU 12 months). The 2 year survivals by stage were
IIB 70%, III 80% and IV 30%. There was no
difference in survival between patients receiving CT
at presentation or at relapse after XRT, between
the CT combinations or between HCG and non-
HCG producing tumours. Survival was better in
patients receiving XRT to all sites of disease
following CT. It is concluded that although CT
produces some improvement in survival the results
are not comparable to those seen in malignant
teratoma and that radiotherapy should remain a
major treatment modality.
Vitamin D3: Phase I study in low-grade
non-Hodgkin's lymphoma
N.L. Gilchrist', D. Cunningham', R.A. Cowan2,
G.J. Forrest', M. Soukop & C.S. McArdle3
'Department of Medical Oncology, 2Biochemistry
and 3University Department ofSurgery, Glasgow
Royal Infirmary, UK.
Vitamin D3 receptors have been demonstrated on
established lines of malignant B, T and non-B non-
T human lymphocytes but absent on normal resting
peripheral B and T lymphocytes. In vitro human
myeloid leukaemia cell lines demonstrated
decreased tumour growth in response to lacOH Vit
D3 or La25(OH)2 Vit D3 (Miyaura et al. (1981)
Biochem. Biophys. Res. Communi. 102, 937).
DeLuca & Kodicek have advanced the theory of
modification of abnormal lymphocytes through Vit
D3 receptors by exogenous ha25(OH)2 Vit D3.
To examine this hypothesis we prospectively
treated 10 patients (6 females and 4 males) with
low-grade non-Hodgkin's lymphoma (2 with CLL,
8 with follicular centrocytic NHL) with 1 ,ug JIaOH Vit
D3 daily. All patients were rebiopsied prior to
commencement of locOH Vit D3 for histological
confirmation and Vit D3 receptor assay. All
patients were seen at monthly intervals and were
assessed clinically, biochemically and haemato-
logically. Two patients with no prior chemotherapy
and bulky lymphadenopathy showed impressive590 BACR/RSM ABSTRACTS
clinical responses. Four patients with prior
chemotherapy showed stable disease. Four patients
with heavy pre-treatment showed progressive
disease. No haematological, biochemical or clinical
toxicity was observed. The absence of tissue Vit D3
receptors appears to correlate positively with Vit
D3 therapy failure.
Theseresults suggestthat IaOHVitD3 mayprovide
non-toxic therapy for low-grade non-Hodgkin's
lymphomas.
Plasma and CSF methotrexate levels during high
dose methotrexate chemotherapy
N.L. Gilchrist', J. Caldwell2. I.D. Watson3,
D. Cunningham', G.J. Forrest' & M. Soukopl
'Departments ofMedical Oncology, 2Anaesthetics
and 3Biochemistry, Glasgow Royal Infirmary.
Glasgow, UK.
Recent intensification of combined modality
therapy in high grade non-Hodgkin's lymphoma
was initiated to lengthen the duration of remission
and to prevent CNS relapse. "High dose"
Methotrexate (MTX) has provided a useful
addition to such regimes. Drug concentrations of
over 10-6M are recommended for adequate
cytotoxicity. (Jolvet et al., 1983, N. Engl. J. Med.,
1094).
To assess plasma and CSF MTX levels we
studied 4 patients (3 females, 1 male) undergoing
combination chemotherapy for high grade NHL.
As part of this regime on Day 10 they received
i.v. bolus MTX (300mgm-2) followed by a 12h
infusion of MTX (1.2gm-2). Prior to commence-
ment of chemotherapy a lumbar indwelling fine
bore CSF catheter was inserted. Paired blood and
CSF samples were obtained continuously for 24h.
(Time 0.5, 15, 30, 45, 60, 90min 2, 3, 4, 5, 6, 8, 12,
15 and 24h). MTX was measured in plasma and
CSF by polarized fluorimetric immunoassay.
Creatinine clearances were 108, 109, 91 and
70mlmin-1. Plasma results showed initial peak
plasma levels of > 10-4M in all patients. In two
patients this dropped to >10- 'M and was main-
tained for 12-24h. But in the further two patients
levels dropped below 10- M. This was not
dependant on renal function. CSF levels were
> 10-6M in those two patients with prolonged and
adequate plasma levels, but <10-6M in those
patients with failure to sustain prolonged levels
>10- M.
These results suggest that "CSF sterilization" is
not automatic in this "high dose" MTX regime.
Plasma levels of MTX should be > 10-M for 12h
to ensure adequate cytotoxic levels in the CSF.
Care should be taken to ensure constant infusion
rate and to give an adequate dose of MTX.
High dose cyclophosphamide (CTX) and VP16
with autologous bone marrow rescue as late dosage
intensification therapy (LDIT) of small cell
carcinoma of lung (SCLC)
D. Cunningham, A. Hutcheon, S.W. Banham,
A. Dorward, A.K. Burnett, S. Ahmedzai, P.
Tansey, R. Stevenson, M. Soukop, S.B. Kaye & N.
Lucie
West ofScotland Lung Group and Woodend
Hospital, Aberdeen, UK.
Ninety-five patients with SCLC received induction
therapy consisting of CTX I gm-2 Day 1,
adriamycin 40mgm-2 Day 1, VP16 lOOmgm-2
Days 1-3, methotrexate 50mgm-2 and vincristine
2mg Day 10, 3 weekly. Twenty-two patients
showing CR or PR to induction therapy after 3
courses were selected to receive CTX 180mgkg-1,
VP16 lgm-2 and mesna 325mgkg-' as LDIT 4
weeks after completion of induction therapy.
Marrow harvested from the patient prior to LDIT
was re-infused 36h later. Prophylactic radiotherapy
4000cGy was given to the primary site in 10 of the
22 patients 6 weeks after LDIT (see Table below).
Major toxicities were; emesis and myelosuppression
100%, diarrhoea 50%, mucositis 36%, skin rash
23% and haematuria 9%. The survival of patients
receiving LDIT was not better than the survival of
comparable groups from the 55 patients who
received 3 course of induction treatment alone. This
pilot study has failed to show any benefit from
LDIT in the management of SCLC.
Table
Response to Chemotherapy Median Alive in
No. of Induction High Dose Survival Remission
patients PR CR None PR PR- CR CR (months) (months)
Limited 16 8 8 5 2 1 8 11 3
Extensive 6 3 3 1 1 1 3 10BACR/RSM ABSTRACTS 591
Recovery of haemopoietic stem cells after in vitro
incubation with cyclophosphamide derivatives used
for bone marrow purging in autologous
transplantation
S. Eridani, E. Batten & B. Sawyer
Department ofHaematology, St Thomas' Hospital,
London SE 1, UK.
Autologous bone marrow transplantation is being
increasingly tried after intensive chemotherapy in
the treatment of neoplastic disorders. Residual
tumour cells, either leukaemic or from other cell
types, can be removed from freshly collected
marrow by different means: cyclophosphamide
derivative like 4HC and Asta Z 7557, have also
been used for this purpose. Human normal marrow
was incubated for 30min with increasing doses of
Asta Z 7557 and then plated to assess granulocytic
and erythropoietic colonies (CFU-GM and BFU-
E). The results obtained so far show that at dosages
up to 5 ig per 2 x 105 cells of Asta Z 7557, a
dosage commonly used to remove leukaemic cells,
there is still a limited amount of colony forming
committed cells. A lower recovery rate was seen
when the drug was left in the medium for the whole
period of culture. In order to test the sensitivity of
the primitive haemopoietic progenitors (CFU-S), in
vivo experiments were also carried out by injecting
lethally irradiated mice with syngeneic marrow pre-
incubated with dosages of the compound, curative
for the L 1210 leukaemic mice. A surviving CFU-S
population varying between 5-10% as compared to
the controls was found with such dosages.
Ifosfamide as single agent therapy in children with
relapsed solid tumours
C.R. Pinkerton, J. Pritchard1, H. Rogers2 & C.
James2
1Hospitalfor Sick Children, Great Ormond Street,
2Department Clinical Pharmacology Guys Hospital,
London, UK.
Long term survival in unresectable and metastatic
tumours in childhood remains disappointing despite
the use of combination chemotherapy and
radiotherapy. The oxazophosphorine, ifosfamide
(IF) has been used with some success in adult
sarcomas and recently, combined with vincristine,
in children (deKraker (1984) Eur. Paediat.
Haematol. Oncol., 1, 47). We have given IF as a
single agent to 18 children, aged 2-15 yrs, with
relapsed or unresponsive solid tumours. Thirteen
had previously received cyclophosphamide (CP)600-
1000mgm-2. Five gm-2 of IF was administered as
a 24h infusion at 14-21 day intervals. Mesna was
given concurrently and for a further 24h and was
highly effective in preventing bladder toxicity.
There was no evidence of hepatic or renal toxicity.
Myelosuppression was not severe and the count had
usually recovered by Day 14. One child had a
generalised convulsion after a dose of 7gm-2
which did not recur at the lower dose. One with pre
existing renal disease became transiently hyper-
tensive. In most cases vomiting was effectively
controlled by high dose dexamethasone. Diagnoses
were Ewings sarcoma (3), Wilms tumour (8),
rhabdomyosarcoma (3), hepatoblastoma (1) hepatic
carcinoma (1), osteosarcoma (1), renal carcinoma
(1). There were 2 complete responses (1 Wilms, 1
Ewings) lasting 5 & 9 months respectively.
(Localised irradiation was given as consolidation in
the latter). There was a partial response in 3 and
only a mixed or no response in 12. Plasma IF levels
were estimated in 8, mean peak conc. during
infusion was 63 ugml -1, elimination tV, 3.1 h. IF
was well tolerated and appeared to be effective in
tumours where combination therapy (including CP)
had failed. The drug may have a role either as a
substitute for CP or as single agent high dose
consolidation treatment.
A method for measuring intestinal damage after
intensive chemotherapy and bone marrow
transplantation using the absorption of 5'Cr EDTA
P. Selby, M. Crofts, R.L. Powles & T.J. McElwain
Department ofMedicine, Royal Marsden Hospital,
Sutton, Surrey UK.
Damage to proliferating intestinal epithelia by
cytotoxic agents is an important side-effect of
cancer treatment and may limit the doses of
treatments that can be given. Gut damage may also
occur after bone marrow transplantation (BMT)
both from the cytotoxic effects of preparation and
from graft versus host disease (GVHD). Efforts to
reduce these effects have been hampered by the
absence of reliable and tolerable measurement
methods for gut damage in these patients (pts). The
absorption of an oral dose of 5"Cr EDTA is a new
method for estimating intestinal permeability and
we have evaluated it as a measure of gut damage
following high dose melphalan (HDM) with
autologous bone marrow transplantation or,
allogeneic bone marrow transplantation. 5"Cr
EDTA (4MBq) was given as an odourless, tasteless,
drink and urinary excretion over 24h was
measured. The test was well tolerated, reliable and
had a narrow normal range of up to 2.9% of
administered dose in 30 untreated cancer pts. It
detected intestinal damage after HDM in 12 pts
with a maximum of 8% administered dose after 9
days returning to normal after 15 days. A dose592 BACR/RSM ABSTRACTS
increase of 20mgm-2 produced a significant
increase in the peak abnormality indicating the
sensitivity of the test. The test also detected damage
due to GVHD and 24h excretion rose to 60% of
administered dose in severely affected pts. Clinical
abnormalities correlated closely with test results
and increased permeability appeared to precede
clinical GVHD. The ease, reliability and sensitivity
of the test should make it useful in the evaluation
of methods designed to reduce gut damage in these
clinical situations.
Transcrecto-sigmoid ultrasonography in the
assessment and management of recurrent cervical
cancer treated with chemotherapy
C.A. Meanwell, E.B. Rolfe, G. Blackledge &
J.J. Mould
Queen Elizabeth Medical Centre, Birmingham, UK.
Fifteen patients with pelvic recurrence of cervical
cancer were assessed clinically and radiologically
using plain radiographs, abdominal ultrasono-
graphy, computerised tomography and transrecto-
sigmoid ultrasonography (TRSU). TRSU was
performed with patients in the left lateral position
using standard transrectal prostate scanners
advanced up to 20cm.
The whole true pelvis was readily demonstrated
and pelvic viscera, tumour masses and diseased
lymph nodes identified. The procedure was well
tolerated by patients.
TRSU showed advantages over clinical examina-
tion and abdominal ultrasonography in its ability
to document tumour dimensions particularly in the
pre-sacral area and in the presence of ascites,
dilated bowel and omental disease. TRSU showed
advantages over CT in its ability to resolve
structures less than 2cm diameter and to produce
images in the coronal or oblique sagittal planes.
TRSU effectively documented the response of
tumours to chemotherapy in 6 out of 10 patients
subjected to post-treatment examinations.
A comparative study of a continuous intravenous
infusion of high dose metoclopramide with
intramuscular chlorpromazine as antiemetic
therapy for patients receiving cytotoxic drugs
D. Cunningham1, A. Hutcheon', M. Soukop',
S.B. Kaye4, N.L. Gilchrist', G.J. Forrest',
C.S. McArdle3 & I.T. Calder2
Departments of'Medical Oncology, 2Pharmacy and
3Surgery, Glasgow Royal Infirmary, 4Department of
Clinical Oncology, Horselethill, Glasgow and
'Department ofMedical Oncology, Woodend
Hospital, Aberdeen, UK.
Ninety-five patients receiving their first course of
cytotoxic therapy entered this double cross-over
antiemetic trial comparing a continuous i.v. infusion
of high dose metoclopramide (HDM) (5mgkg-')
with i.m. chlorpromazine (25mg). Seventy-four
patients completed the cross-over, 33 of whom
received cytotoxic therapy which included cis-platin
or cis-platin analogues. In these 33 patients,
complete control of vomiting occurred in 27% with
HDM and 21% with chlorpromazine. Nausea was
less severe with HDM (P<0.05) and a significant
number of patients preferred HDM as an
antiemetic (P<0.01). Forty-one patients received
cytotoxic therapy without cis-platin with complete
control of vomiting in 44% given HDM and 48%
given chlorpromazine. In this group no significant
differences in the control of nausea or vomiting
were observed and there was no overall patient
preference.
For patients receiving cytotoxic therapy
containing cis-platin HDM was a better antiemetic
than chlorpromazine. In other cytotoxic regimes
both agents had similar antiemetic efficiency but
chlorpromazine is recommended because it is
cheaper and easier to administer.
Experience of angioimmunoblastic lymphadenopathy
(AILD) and its possible relationship to T cell
lymphoma, in Sheffield
M.S. Dorreen, N. Rooney' & B.W. Hancock
University Departments ofMedicine and 'Pathology,
Royal Hallamshire Hospital, Sheffield SJO 2JF, UK.
Angioimmunoblastic lymphadenopathy (AILD) was
diagnosed in 7 previously untreated patients (pts)
referred to the Royal Hallamshire Hospital between
1979 and 1983. The dual pathology of
AILD+malignant lymphoma (ML) was diagnosed
in 2 additional pts. On a subsequent review of all
histological material, the diagnosis of AILD was
reaffirmed in 5/7 cases. In 3 cases (including the 2
pts. originally diagnosed as AILD+ML) the
diagnosis was reclassified as T zone ML, although
many of the histological features closely resembled
those of AILD. In the case of the 9th pt, a 70 year
old male, the diagnosis of lymphoproliferative
disease was rejected. The clinical and laboratory
features of the 8pts (5 male, 3 female) retained in
the study were indistinguishable, regardless of the
pathological diagnosis. The mean age was 65 years
(range: 45-75). "B" symptoms were present in 7pts,
of whom 4 presented seriously ill. Other complaints
included pruritus (3 pts) and rash (2pts).BACR/RSM ABSTRACTS 593
Concurrent medication was of possible aetiological
significance in 2 cases. Generalised lymph-
adenopathy was found in 7 and palpable hepato-
splenomegaly, in 6pts. Intrathoracic disease was
revealed on the X rays of 5pts (lymphadenopathy
in 4 and parenchymal infiltration in 1 pt). The
mean ESR was 45 (range: 4-113). The direct
Coomb's test was positive in 3/5 instances.
Polyclonal hypergammaglobulinaemia was noted in
6 cases. Twopts observed without therapy remain
well at 12 months' follow up. One pt, with T zone
ML, died within 4 months of presentation. Three
pts were initially treated with prednisolone; 2 have
died, one of bronchopneumonia, the other (who
presented with AILD) of widespread ML, both
within 15 months of first diagnosis; the 3rd pt has
undergone histological transformation to a T
immunoblastic ML and is receiving treatment for
this. Two pts with T zone ML are in complete
remission following intensive combination
chemotherapy. These results suggest: 1) the accrual
of a relatively large number of pts with AILD (4/5
since January 1982) within a single health
authority, may indicate a higher UK incidence of
AILD than hitherto realised and (2) the clinical and
pathological behaviour of AILD suggest a close
relationship with certain forms of T cell lymphoma.
Enzymatic and metabolic profiles in a cachexia
model
M.J. Tisdale', R.A. Brennan1 & K.C.H. Fearon2
1CRC Experimental Chemotherapy Group,
Department ofPharmacy, University ofAston,
Birmingham B4 7ET, 2Department ofOncology,
University ofGlasgow, Glasgow GL2 94Y, UK.
The MAC 16 is a chemically induced transplantable
adenocarcinoma of the colon, which produces
extensive weight loss in tumour-bearing mice. This
weight loss appears to arise from metabolic effects
of the tumour, since food intake is not decreased
prior to or during weight loss.
We have considered the MAC, 16 to be an
appropriate model to study the effect of ketosis on
the protection of host tissues during the cachectic
process. The MAC 16 tumour possesses the three
enzymes necessary for ketone body metabolism: 3-
oxoacid-CoA transferase, acetoacetyl CoA thiolase
and 3-hydroxybutyrate dehydrogenase, although the
activity of the first two enzymes is significantly
lower than that found in normal colon. There is no
significant difference in the enzyme content of non-
involved tissues; heart, liver, kidney, brain and
colon; between tumour-bearing and non-tumour
bearing animals.
Within three weeks after transplantation of the
MAC 16 tumour mice weigh an average 5 g less
than non-tumour bearing mice, although the
average weight of the tumour is only 1 g. During
this period blood glucose, lactate, carnitine,
acetoacetate and 3-hydroxybutyrate levels in
tumour-bearing mice are not significantly different
from controls. This suggests a block in the normal
metabolic process of ketosis induction host weight
loss.
Comparison of in vitro sensitivity in leukaemic cells
from blood, bone marrow and lymph node samples
M.C. Bird, E.D. Gilby & A.G. Bonsanquet
Department ofClinical Investigation, Royal United
Hospital, Combe Park, Bath BA] 3NG, UK.
A dye-exclusion chemosensitivity assay previously
described (Bird et al. (1984) Br. J. Cancer, 50, 258)
has been used to determine the chemosensitivity of
leukaemic cells from simultaneously taken blood
(Bl) and bone marrow (BM) samples of 6 patients
(3 acute lymphoblastic (ALL), 2 chronic
lymphocytic (CLL) and 1 acute myeloid leukaemia
(AML). Control viabilities in the assay were similar
for the two sites, with a mean of 51% (range 4-
86%) for BM, and 59% (22-94%) for Bi samples.
Fifteen different drugs have been tested at between
one and 6 concentrations per drug (mean of 5
drugs per patient), giving a total of 98 drug
sensitivities for comparison. The overall chemo-
sensitivity of BM and Bl leukocytes was very
significantly correlated (r= 0.630; P<0.001).
Correlation coefficients (r) for the three disease
categories were 0.881, 0.616 and 0.517 for CLL,
AML and ALL patients respectively. Samples were
scored as being sensitive (S; <30% surviving
tumour cells) or resistant (R) for each drug
concentration tested. Sensitivity was similar for Bl
and BM samples in 89 cases (81 RIR, 8 S/S). Of
the remaining 9 data points, 8 were resistant in B1
samples but sensitive in BM. Chemosensitivity was
also compared in leukaemic cells from peripheral
B1 and lymph node biopsy from a single CLL
patient. Control viabilities in the assay were 47%
for lymph node and 56% for Bl leukocytes. A total
of 22 drug sensitivities from 9 different drugs could
be compared, and chemosensitivity was again very
significantly correlated (r=0.748; P<0.001). Deter-
mination of sensitivity was in complete agreement
with 18 RIR and 4 S/S determinations. The results
indicate that samples from any of these three
sources could be used equally well to obtain chemo-
sensitivity data for predictive use.594 BACR/RSM ABSTRACTS
Possible mechanism of selective toxicity of
1-naphthol to human colonic tumour tissue compared
to normal colonic tissue
M. d'Arcy Doherty, G.D. Wilson & G.M. Cohen
Toxicology Unit, The School ofPharmacy,
University ofLondon, London WCJ IAX, UK.
The aim of this study was to investigate the
possible mechanism(s) of selective toxicity of 1-
naphthol to short-term organ cultures of human
colonic tumour tissue compared to normal colonic
tissue from the same patients (Biochem. Pharmacol.
(1983) 32, 2363). At low non-toxic concentrations
of 1-naphthol (201M), short-term organ cultures of
normal human colon formed predominantly 1-
naphthyl sulphate whereas colonic tumour tissue
formed more 1-naphthyl-fl-D-glucuronide. At higher
concentrations (1 mM), which were selectively
toxic to the tumour tissue, conjugation of 1-
naphthol to its non-toxic glucuronic acid and sul-
phate ester conjugates was significantly greater in
the normal tissue than the tumour tissue, suggesting
an impaired Phase II conjugative metabolism in the
tumour tissue. The impaired detoxication pathways
resulted in a marked accumulation of unmetabolised
1-naphthol (42+ 12nmolmg- protein) in the
tumour tissue compared to that found in the
normal tissue (5+3 nmolmg- 1 protein) following
incubation with 1-naphthol (1 mM) for 48h. The
higher levels of 1-naphthol in the tumour tissue may
then exert their toxicity by metabolic activation
most probably via naphthoquinones. Some evidence
for this was obtained by the potentiation of 1-
naphthol toxicity by dicoumarol, an inhibitor of
DT-diaphorase. In addition, [1-'4C]-l-naphthol was
activated by short-term organ cultures of both
normal and tumour tissue to covalently bound
products. The level of binding was greater in the
tumour tissue suggesting greater conversion to
reactive products in this tissue. These results may
also be explained by a greater susceptibility of the
tumour tissue to oxidative stress.
A comparison of vitamin A binding in human benign
and malignant prostate
D. Boyd, G.D. Chisholm & F.K. Habib
Department ofSurgery, University Medical School,
Teviot Place, Edinburgh EH8 9AG, UK.
Specific binding sites for [3H] vitamin A alcohol
(retinol) have been detected and characterised in the
cytosol of human, benign prostate gland. In
addition the expression of these sites in the benign
and malignant disease has been compared.
Retinol binding sites sedimented to the 2S position
on sucrose gradients and were heat/protease
inactivated. Competition studies indicated the
specificity of binding; unlabelled retinal, retinoic
acid and various steroids had little effect on [3H]-
retinol bound. Scatchard analysis revealed ligand
association to be of high affinity (30-40nM). The
binding characteristics in malignant tissue were
found to be similar to those observed in the benign
gland.
A cytosol assay was developed to compare retinol
binding in benign and malignant gland. The assay
was linear with protein concentration over the
range 0.1-1.Omgml-'. Inter- and intra- assay
variations were 5.8+3.8 and 9.8+6.9% respec-
tively. Storage of prostate at -70°C for a period of
8 weeks had no adverse effects on the assay.
Retinol binding in benign and malignant prostate
was compared and found to be suppressed in the
malignant gland (benign=4.0+ 1.8; malignant=
1.7+1.6pmolmg-' protein X+s.d.); these values
were shown to be statistically different by the
Mann-Whitney U-test. In contrast, no trend was
observed between retinol binding and tumour
differentiation.
Immunohistochemical assessment of murine
antipancreatic cancer monoclonal antibody DD9E7
A. Grant', E. Heyderman2, P. Harris1 &
J. Hermon-Taylor'
'Department ofSurgery, St George's Hospital
Medical School and 2Department ofHistopathology,
St Thomas's Hospital Medical School, London, UK.
Using a novel immunisation regime, we have
generated a number of murine monoclonal
antibodies against human pancreatic exocrine
cancer (GER) which appear to have sufficient
selectivity for pancreatic cancer cells to be of
diagnostic and other potential use. Supernatants
from these hybridomas were screened on formalin-
fixed paraffin-embedded tissue sections. The initial
screen was carried out on normal non-neoplastic
human pancreas and the original GER pancreatic
tumour. Five supernantants stained malignant
epithelium in pseudoductules as well as normal
pancreatic duct epithelium. DD9E7 produced the
most intense staining of malignant epithelium and
was further tested against other pancreatic
adenocarcinomas and a wide variety of non-
neoplastic and malignant tissues in both fixed and
frozen tissue sections. The distribution of staining
in other tissues, in particular colon, breast and skin
carcinomas, suggested it was not recognising CEA
or EMA. Consistent staining of polymorphs andBACR/RSM ABSTRACTS 595
macrophages in all sections suggested NAC-like
material was being identified but a different pattern
of staining was produced to that found with
a monoclonal against a shared NCA/CEA
determinant.
Evidence for the lysosomotropic action of an
antibody directed drug conjugate
M.C. Garnett, E. Jacobs, M.J. Embleton &
R.W. Baldwin
Cancer Research Campaign Laboratories, University
ofNottingham, University Park, Nottingham NG7
2RD, UK.
The preparation and properties of a methotrexate-
human serum albumin-antibody conjugate which
retains both antibody binding activity and complete
drug cytotoxicity has been previously reported
(Garnett et al. (1983) Int. J. Cancer, 31, 661). It has
been proposed that drug conjugates would be taken
up into cells and the drug released by lysosomal
enzymes (De Duve et al. (1974). Biochem.
Pharmacol., 23, 2495). To test this hypothesis for
our conjugate we have assessed the ability of the
various inhibitors of lysosomal enzymes to affect
the cytotoxicity of both conjugated and free
methotrexate to target cells expressing the relevant
antigen in a "24h treatment" assay.
Ammonium chloride, which reduces lysosomal
enzyme activity by raising lysosomal pH, reduced
the cytotoxicity of both free and conjugated
methotrexate. The effect on conjugate was greater,
but ammonium chloride also affected cell growth in
general. Leupeptin, an inhibitor of both serine and
cysteine cathepsins, reduced conjugate cytotoxicity
to one fortieth of the uninhibited level with no
effect on free methotrexate. E64, a specific inhibitor
of cysteine cathepsins, had a similar but smaller
effect. Pepstatin A and chymostatin, specific
inhibitors of aspartic and serine cathepsins
respectively, had no significant effect on the
cytotoxicity of the conjugate. These results indicate
a lysosomal mechanism of action mediated by
cysteine cathepsins, although the contribution of
other enzymes cannot be ruled out by these
experiments.
Influence of bestatin, poly I:C, PPD and a
pyrimidinone on growth and metastasis of rat
mammary carcinoma
M.V. Pimm & R.W. Baldwin
Cancer Research Campaign Laboratories, University
ofNottingham, Nottingham NG7 2RD, UK.
Bestatin, Poly I:C, PPD and a pyrimidinone (2-
amino-3-bromo-6-phenyl-4-pyrimidinone, ABPP,
Milas et al. (1983) Clin. Exp. Met., 1, 213) have
been tested for therapeutic effectiveness against the
metastasising rat mammary carcinoma Sp4.
Bestatin (5mgkg-1 i.p. twice weekly) restricted
development of post-surgical lymph node
metastases and poly I:C: (1 mgkg-1 i.p.) 4, 3, and 2
days before i.v. tumour cell challenge restricted
development of pulmonary deposits. Rats pre-
immunised with BCG vaccine and showing DTH
reactions to PPD, rejected Sp4 cells injected s.c.
with PPD. Moreover, i.v. injection of free or
liposomally encapsulated PPD restricted the
development of post-surgical lymph node
metastases and pulmonary tumour deposits. In
contrasttotheabove,ABPP(250mgkg 1i.p.)4,3,and
2 days before i.v. cell injection failed to suppress
development of pulmonary deposits. With s.c.
tumour challenge ABPP had no influence on
tumour take or growth rates. Additional tests were
carried out to examine whether ABPP could
augment the tumour suppressive effect of DTH
reactions to PPD but the effect was abrogated
rather then enhanced. To determine whether ABPP
influenced the DTH response itself, BCG-immune
ABPP treated rats were tested i.d. with graded
doses of PPD. The response was significantly
reduced in ABPP treated rats compared with
controls.
These studies have failed to detect anti-tumour
effects of ABPP against the rat mammary
carcinoma Sp4, although this tumour is suppressed
by Bestatin, poly I:C and PPD. In addition the
indication is that ABPP might have some
suppressive effect on delayed hypersensitivity
reactions.
Tumour-induced suppression of delayed-type
hypersensitivity is independent of
cyclophosphamide-sensitive suppressor cells
L.C. McIntosh, L.M. Morrice, Y. Udagawa &
A.W. Thomson
Immunopathology Laboratory, Department of
Pathology, University ofAberdeen, Aberdeen Royal
Infirmary, Foresterhill, Aberdeen AB9 2ZD, UK.
The delayed-type hypersensitivity (DTH) response
to sheep red blood cells and ovalbumin was
markedly reduced in mice bearing the Landschiitz
ascites carcinoma. Similar effects were obtained by
administering cell-free ascitic fluid or serum from
tumour-bearing animals together with antigen in
the footpad; injection of normal mouse serum had
a much less pronounced effect. Treatment with high
dose cyclophosphamide prior to immunization did
not abolish the effect. Splenic lymphocyte
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transformation in response to various mitogens was
suppressed in tumour-bearing animals while
production of a lymphokine (lymphocyte-derived
chemotactic factor) remained unimpaired. There-
fore, the observed suppression of DTH was not
dependent on cyclophosphamide-sensitive T
suppressor cells or on the administration of
immunosuppressive factor(s) during the induction
stage of the response. The tumour may be exerting
its immunosuppressive effect by inhibiting
lymphocyte proliferation whilst failing to inhibit
production of T-cell derived chemotactic factor.
Stress and breast cancer
T.J. Priestman', S.G. Priestman1 & C. Bradshaw2
1Department ofRadiotherapy & Oncology, Queen
Elizabeth Hospital, Birmingham B15 2TH, West
Midlands Cancer Research Campaign Clinical Trials
Unit, University ofBirmingham, UK.
In order to assess whether exposure to stress was
associated with an increased risk of breast cancer,
100 women presenting with carcinoma of the breast
completed a standard life events inventory
documenting life stresses experienced during the
previous three years. The same questionnaire was
completed by 100 women presenting with benign
breast lumps and 100 healthy controls. Both groups
of patients with breast disease also completed the
Eysenck personality inventory. There was no
difference in the number of stressful life events
experienced by the patients with benign and
malignant breast lesions and the nature and severity
of those stresses encountered were similar for both
groups. The personality indices were also the same
for both groups. The controls, however, recorded
singnificantly higher levels of stress exposure than
the patients with breast disease. On the basis of
these results there is no evidence to support the
hypothesis that stress predisposes to breast cancer
development or presentation.
Viral infections in patients receiving adjuvant
chemotherapy for breast cancer
E.H. Dykes', R.G. Somerville2. D.C. Smith3 & C.S.
McArdlel
Department ofSurgery, IRoyal and 3Victoria
Infirmaries, 2Department of Virology, Belvidere
Hospital, Glasgow, UK.
Viral infections produce significant morbidity and
mortality in immuno-suppressed transplant patients
(Ho (1977) Arch. Virol., 5, 1). Adjuvant chemo-
therapy is also known to have immunosuppressive
effects. The aim of this study was to determine the
incidence of viral infection in patients receiving
cytotoxic chemotherapy following mastectomy for
breast cancer.
One hundred and twenty-four patients attending
a breast clinic were studied. Sixty-four patients were
currently receiving cytotoxic chemotherapy (CMF),
the remaining patients acting as controls. Blood
samples were taken at 3 monthly intervals and
standard screens for antibodies to respiratory
viruses performed. A 4-fold increase in antibody
titre between two consecutive samples was
considered evidence of recent infection.
Patients receiving CMF had 123 infections during
444 (1 per 3.6) patient months of study. In controls
63 infections occurred during 495 (1 per 7.8) patient
months (P<0.05). The common viruses
encountered were herpes simplex (26%), influenza
A (17%) and para influenza (13%). Less common
viruses encountered in the CMF patients included
RSV (13%), CMV (8%), M. pneumoniae (6%).
These results show that patients receiving
cytotoxic chemotherapy are at high risk of viral
infection and such infections may add to morbidity
during treatment.
Interim results of treatment of breast cancer with
breast conservation for all patients
A.S. Bulman, R.H. Phillips & H. Ellis
Departments of Surgery and Radiotherapy,
Westminister Hospital, London SWIP2AP, UK.
Randomised studies of mastectomy versus breast
conservation are proving difficult for doctors and
patients in the United Kingdom to accept, and
criteria for selecting patients for one treatment or
the other are not agreed. We have therefore
adopted a policy of primary treatment with breast
conservation for all female patients presenting to
this Unit with carcinoma of the breast since March
1979. One hundred and fifty-nine patients had local
excision of the tumour with radical radiotherapy up
to December 1982. At 1-4 years life tables have
indicated overall and recurrence-free survival rates
comparable to those expected after mastectomy
(Cancer Research Campaign - Kings/Cambridge
Trial) - for early breast cancer. Cancer Research
Campaign Working Party. Lancet (1980), ii, 55.
Radical versus modified radical mastectomy for
breast cancer. Turner, Swindell, Bell et al. (1981)
Ann. R. Coll. Surg. Engl. 63, 239. Local recurrence
has occurred in 4/43 patients presenting with Stage
I disease, 9/105 Stage II and 1/11 Stage III. Only 4
patients have required mastectomy to control breast
recurrence, and of the 9 who have died, only 2 did
so with local disease.BACR/RSM ABSTRACTS 597
Phase II study of CB3717 in advanced breast cancer
V. Macaulay, A.H. Calvert, & I.E. Smith
Medical Breast Unit, Royal Marsden Hospital,
Fulham Road, London, UK.
CB3717 is a quinazoline-based folate analogue
which acts by tight-binding inhibition of
thymidylate synthetase. Based on phase I data, a
phase II study has been started in advanced breast
cancer. CB3717 was given at 400mgm-2 q21 with
dose reduction for impaired glomerular filtration
rate (GFR) or elevated alkaline phosphatase (AP).
Seventeen patients have been entered and so far 11
are evaluable, of whom 8 had previous combination
chemotherapy. Two patients achieved PR for 13
and 20 weeks, and there were 2 minor responses
(<50% reduction of 10+ and 17 weeks. Three
patients had SD and 4 had PD, including one
mixed response. Response rates by metastatic site
are: soft tissue 3/11, visceral 3/11, osseous 1/4.
Median time to progression is 9 weeks (4+ -21).
Nephrotoxicity was dose-limiting with 20-50% fall
in GFR in 71% and >50% in 14%. No patient
required dialysis and there is early evidence of
reversibility in one patient. Elevation of liver
function tests (LFTs) was seen in 92%, affecting
ALT (<3 x normal in 50% of patients,
>3x normal in 33%) but also AP (75% and 0%)
and Gamma GT (58% and 17%). This was
associated with malaise, which occurred 3-10 days
after treatment, in 46% of patients. Prednisolone
cover relieved malaise in all cases. LFTs
spontaneously improved in 4 of 7 patients given
more than 2 courses. Other toxicities included
nausea/vomiting (19%) and conjunctivitis (12.5%);
myelotoxicity was not seen (median nadir Hb.
9.9gdl-1, WBC 6.4, platelets 247x 1091-1. These
preliminary results confirm that CB3717 is active in
advanced breast cancer, with minimal myelo-
suppression but significant renal and symptomatic
hepatic toxicity. Responses are brief in these heavily
pre-treated patients; the drug may be more effective
as first-line chemotherapy.
Mitomycin C and vinblastine in the treatment of
advanced breast cancer
J.A. Radford & R.D. Rubens
Imperial Cancer Research Fund Breast Cancer Unit,
Guy's Hospital, London, SE] 9RT, UK.
Response of advanced breast cancer to secondary
chemotherapy is poor, but response rate of 40%
has been reported (Konits et al. (1981), Cancer. 48,
1295).Wehavetreated35patientswithadvancedbreast
cancer progressive after at least one prior chemo-
therapy regimen, with mitomycin C 12 mgm-2
(max. 20mg) and vinblastine 6mg m-2 (max. 10mg)
i.v. every 3 weeks. Twenty-six had received prior
endocrine treatment and all had received prior
chemotherapy (21 one and 14 two or more regimens,
including Adriamycin, mitoxantrone, or combined
cyclophosphamide + methotrexate + 5-fluorouracil).
Five patients had received interferon and 13 radio-
therapy to metastases. Twenty-three patients are
evaluable after 2 or more courses. Seven (32.8%)
have responded (1 CR, 6PR). Response at sites
were: breast 6/17, skin 5/18, lymphatic 3/14, bone
0/10, liver 0/4, lung 0/7, pleura 1/2. Toxicity was
mild. Eight had nausea or vomiting<WHO grade
2, one had alopecia, WHO grade 1 and one had
diarrhoea, WHO grade 1. Median lowest recorded
Day 22 white blood cell count was 3.75 x 1091-1,
platelets 172 x1091 - and percent projected doses
given were mitomycin C 86.0% and vinblastine
87%.
Mitomycin C+ vinblastine is active as second or
third line chemotherapy for advanced breast cancer
with minimal toxicity. Accrual to this study
continues.
Bone scintigraphy in breast cancer: A nine year
follow-up
I.H. Kunkler, M.V. Merrick and A. Roger
Departments ofClinical Oncology and Nuclear
Medicine, Western General Hospital, Edinburgh,
UK.
The results of bone scintigraphy (BS) in 465 women
with histologically proven breast cancer were
correlated with tumour size, nodal status (NS),
clinical course and survival. Median follow-up
periods were 26, 26 and 20 months respectively for
BS positive (+), BS negative (-) and BS
benign/equivocal (B/E). The maximum follow-up of
the whole group was 9 years. (See Table below.)
Table
Staging To- I T2 T3 T4
BS N+ N- N+ N- N+ N- N+ N-
No (%) No (%) No (%) No (%) No (%) No (%) No (%) No (%)
BS (-) 20 (77) 57 (86) 85 (72) 81 (72.3) 20 (50) 21 (84) 33 (56) 11 (58)
BS(+) 2 (8) 1 (2) 10 (8.5) 7 (6.3) 7 (17.5) 2 (8) 12 (20) 3 (16)
BS (B/E) 4 (15) 8 (12) 23 (19.5) 24 (21.4) 13 (32.5) 2 (8) 14 (24) 5 (26)598 BACR/RSM ABSTRACTS
The average incidence of BS(+) was 10.1%.
Skeletal metastases (SM) were eventually confirmed
radiologically or at post-mortem in 17.6% of the
patients but had been identified by BS at presentation
in only 9.5%. 13.6% of BS(+) failed to develop
confirmatory evidence of metastases during follow-
up. No correlation was found between histological
NS and BS(+) (P=0.79). No significant difference
was detected between BS(-) and BS(B/E) in the
subsequent development of SM (P=0.5). The
actuarial survival over 9 years was significantly
shorter for BS(+) than B(-) or BS(B/E) (P=0.03).
There is no evidence that routine BS affects the
management of newly diagnosed breast cancer.
Unless an algorithm can be developed which
requires this information, routine BS is not
justified. It should be reserved for patients with
clinical suspicion of metastases and for clinical
trials.
Tamoxifen as primary therapy for elderly women
with breast cancer
S.G. Allan', U. Chetty2, A.P.M. Forrest2,
A. Rodger', J.F. Smyth1 & R.C.F. Leonard1
'University Department ofClinical Oncology,
Western General Hospital, 2University Department
ofClinical Surgery, Royal Infirmary, Edinburgh,
UK.
Since 1977, 105 women, mean age 76.3, with
histologically confirmed breast carcinoma of any
stage have received primary therapy with tamoxifen
10mgtds indefinitely or until tumour progression
(range 5-55 months). Thirty-eight patients, 36%,
had other major system disorders e.g. vascular
disease, dementia, anthropathy.
One hundred patients are evaluable for response
with known oestrogen receptor (ER) status in 37
(median ER 300fmolmg-1 cytosol prot). The 70%
response rate (43% CR) in the known ER positive
group is not dissimilar to the overall response rate
(39% CR). Median time to best response was 15.5
weeks (range 6-135). Median duration of tamoxifen
therapy is 23 months (range 5-48) for CR patients,
18 months for PR (range 6-55) and 15 months for
the no change group. Twelve of the 68 responders
(2 CR, 10 PR) have relapsed giving a 19 month
median response duration (mean 24 months, range
9-55 months). Ten patients had progressive disease
despite tamoxifen. Locally advanced disease
appeared to influence response with only a 53%
response rate in the "T4" group.
Side effects to tamoxifen were absent in 67%
with dry mouth 13%, transient nausea 10%,
vomiting 4%, fatigue 10%, vaginal dysaesthesia 2%
and vaginal discharge 2%. Only 5/14 deaths were
due to carcinoma, these being in non-responders.
DNA interstrand cross-linking and drug sensitivity to
cis-diamminedichloroplatinum II (CDDP) in human
ovarian cancer cell lines in vitro
B.G. Ward & B.T. Hill
Laboratory ofCellular Chemotherapy, Imperial
Cancer Research Fund, London, WC2A 3PX, UK.
CDDP has proven to be effective agent against
human epithelial ovarian cancer. No study of the
mode of action of the drug has yet been reported
using a human tumour model system.
Four human epithelial ovarian cancer cell lines
have been assayed for sensitivity to CDDP in vitro
by the soft agar colony-forming assay of
Courtenay. (Courtenay & Mills (1978) Br. J.
Cancer, 37, 261). Assays were performed after the
cells were incubated for I or 24h with CDDP and
the results expressed as the concentration of drug
required to limit colony formation to 50% of
control untreated cells (ID50). In the 4 lines, mean
ID50 values ranged from 280ngml-P to 4.34ugml-
(1 h exposure) and from 26ngml1 to 680ngml1
(24h exposure).
Following a I h incubation with CDDP at
various concentrations single cell suspensions were
exposed to a known X-ray dose to induce DNA
single strand breaks. DNA interstrand cross-linking
was then measured against these by the alkaline
denaturation-renaturation method of Jolley and
Ormerod. (Jolly & Ormerod (1973) Biochim Biophys
Acta., 308, 242). Results are expressed in rad
equivalents. This technique permitted quantitative
comparative studies with these 4 cell lines. In each
case, following a 1 h exposure to CDDP, cross-links
formed linearly with increasing dose, reaching a
maximum 4-8 h after drug removal. Mean
interstrand cross-link formation ranged from 88+9
to 233 +26 rad equivalents at 4hrs after a 1 h
exposure to 40jugml -1 CDDP and these levels
reflected the relative drug sensitivities of the cell
lines, with one exception. These results suggest that
DNA interstrand cross-links may be associated with
the cytotoxicity of CDDP but do not support a
causal relationship.
Verapamil enhances the sensitivity to adriamycin and
VP16-213 of human lung cancer in vitro
C.A. Fetherston, S. Merry, S.B. Kaye &
R.I. Freshney
Department of Clinical Oncology, University of
Glasgow G12 9LX, UK.
In some experimental tumour models resistance to
adriamycin and VP16 has been attributed to
enhanced cellular drug efflux, and sensitivity to
adriamycin has been increased using calcium
channel blockers, including verapamil. In thisBACR/RSM ABSTRACTS 599
study, the ID50 values of 6 continuous human non-
small cell lung cancer cell lines to 7 drugs
(adriamycin, actinomycin D, VP16-213, vincristine,
5-FU, mitomycin C and melphalan) were
determined. Cells were seeded onto microtitre plates
and, after 72h, were exposed to drug for a further
72h followed by a recovery period of 120h. Cell
number at the end was determined by tritiated-
leucine incorporation into the trichloroacetic acid
insoluble fraction (Freshney et al. (1975) Br. J.
Cancer, 31, 89). Of 3 cell lines resistant to
adriamycin (L-DAN, WIL, A549) a non-cytotoxic
concentration of verapamil (6.6,uM) caused a 6-10
fold decrease in ID50 in 2 of the lines. In H125
(sensitive) 6.6 pM verapamil had no effect. With
VP-16, 6.6pM verapamil caused a 3-6 fold decrease
in ID50 in 3 cell lines resistant to the drug (WIL,
A549, H125), although in another VP16 resistant
line (SK-MES) verapamil had no effect. Four of
the cell lines used were also resistant to vincristine,
but 6.6MM verapamil only caused a 2-fold
reduction in ID50 of one cell line (WIL). These
results demonstrate that verapamil is able to
increase the sensitivity of some, but not all, human
lung carcinoma cell lines, and may indicate a
potential role for verapamil in circumventing
clinically observed drug resistance. Since verapamil
had an effect on only some of the cell lines,
different mechanisms of resistance may be in
operation. Studies on membrane transport as one
possible mechanism are in progress.
Factors affecting drug release from
adriamycin-loaded protein microspheres
N. Willmott', J. Cummings2, J.F.B. Stuart1 &
A.T. Florence'
'Department ofPharmacy, University ofStrathelyde
and 2Department ofClinical Oncology, University of
Glasgow, UK.
Microspherical drug delivery systems hold out the
possibility of increasing the specificity of cytotoxic
anti-cancer agents by (a) tissue localisation through
capillary blockade of particular organs with
particles of requisite size and (b) control of drug
release from carrier. In order to examine the latter
point a system was developed that involved
immobilising drug-containing microspheres on a
glass wool column subjected to aqueous buffer at a
constant flow rate, and analysis of the eluate for
adriamycin (Adx).
Time taken for elution of 50% of Adx (T,0),
measured by total fluorescence and high pressure
liquid chromatography, was compared with regard
to (a) protein (albumin, haemoglobin) used as the
microsphere matrix, (b) concentration of cross-
linking agent (glutaraldehyde) used in microsphere
formation and (c) microsphere size. It was found
that for Adx-loaded microspheres prepared using
1% glutaraldehyde, albumin (T =3.5h) gave more
protracted drug elution than haemoglobin or free
drug (T50 =2.6h and 2.2h). Moreover, for albumin
microspheres, increasing glutaraldehyde concen-
tration and particle size both decreased elution
rates, although the maximum T,0 was still only 5h.
Total drug content was measured after digestion
of microspheres with trypsin and in this case total
fluorescence measurements were a reliable measure
of Adx content only under certain conditions;
namely, using albumin as matrix protein and < I%
glutaraldehyde. Under such conditions it was
observed that not all drug was released in vitro.
These data are consistent with in vivo results
showing an initial, relatively rapid release of a
proportion of drug from intact microspheres, with
the remainder only becoming available when the
structural integrity of the particles is compromised.
A study of adriamycin resistance using human
ovarian tumour cell lines
E.M. Gibby, 0. Boyse & B.T. Hill
Laboratory ofCellular Chemotherapy, Imperial
Cancer Research Fund, Lincoln's Inn Fields, London,
WC2A 3PX, UK.
Ovarian carcinoma is the fifth most common cause
of death from cancer amongst women in the United
Kingdom. A problem in treating this disease is the
development of resistance to drugs used as a second
line agents. This is particularly marked for
adriamycin (ADR) so we are using experimental
models of human ovarian cancer to investigate
response to ADR in vitro. Three human tumour
continuous cell lines, established directly from
ovarian cancer biopsy specimens have been studied.
There is an inherent heterogeneity of response to a
24h exposure to ADR using the Courtenay
clonogenic assay with IC50 values ranging from 10-
35ngml-'. Duration of drug exposure is an
important determinant of drug-induced cytotoxicity.
In one cell line (SK-OV-3) a comparison of IC50
values for 1 h and 24h exposures to ADR indicates
a significantly higher "CxT" value for the longer
exposure. The different responses to ADR shown
by the 3 cell lines cannot be explained by the 5-fold
variation in net drug uptake of this drug by the
cells, measured fluorimetrically.
To study the development of resistance to ADR
in vitro, a series of sublines of the SK-OV-3 cell line
have been produced by intermittent, repeated
exposures to a range of clinically-achievable plasma
drug levels. The subline treated with the highest
concentration (6 x 200ngml -1) exhibits an
approximate 10-fold order of resistance compared600 BACR/RSM ABSTRACTS
with the parent cells. This sub-line exhibits no
cross-resistance to 4'-deoxy-ADR; is sensitive to a
lower concentration range of this 4'-deoxy
derivative compared with ADR; shows no defect in
ADR uptake measured fluorimetrically; and the
resistance to ADR is not overcome by verapamil.
Alternative mechanisms implicated in this
expression of drug resistance are now being
investigated.
Resistance to antimicrotubular drugs in CHO cells
J.R. Warr, F. Brewer, K. Adams & M. Anderson
Biology Department, University of York, York
YOJ 5DD, UK.
Several aspects of resistance to antimicrotubular
anticancer agents in Chinese hamster ovary (CHO)
cells have been studied. The drugs studied include
vincristine, vindesine and taxol. Mutants have been
selected either by a single challenge to a high drug
concentration or by prolonged exposure to
gradually increasing drug concentrations over a
period of months.
Stable mutants selected by the former method
show several interesting features in their cross-
resistance patterns. We have previously reported
that some vincristine resistant strains are hyper-
sensitive to the microtubule stabilising drug taxol
(Warr et al. (1984) Cell. Biol. Int. Rep., 8, 591) and
we have now analysed large numbers of
independently isolated vincristine or taxol resistant
mutants for their pattern of reciprocal cross-
resistance or sensitivity. There is not a consistent
pattern of reciprocal sensitivity. Genetical analysis
(by complementation studies in somatic cell
hybrids), analysis of the cross-resistance patterns to
other classes of antitumour drugs and other
phenotypic differences between resistant cell lines
suggest that mutations in several different genes
may be involved in resistance to vinca alkaloids in
CHO cells.
Selection for resistance to vincristine by
prolonged exposure to the drug has produced cell
lines with around a hundred fold increase in
vincristine resistance. Resistance is unstable during
prolonged culture in drug-free medium and the cell
lines are shown to have reduced vincristine uptake.
Derivation and characterisation of a multidrug
resistant line of human small cell lung cancer cells
P. Twentyman, N. Fox & N. Bleehen
MRC Clinical Oncology and Radiotherapeutics Unit,
Hills Road, Cambridge, UK.
There are numerous reports in the literature of the
production of drug-resistant cell lines by growth in
increasing concentrations of various drugs. The
great majority of such reports describe cell lines of
mouse or hamster origin and those which describe
human cells are almost exclusively confined to
leukaemias and lymphomas. Although we have
recently derived, without difficulty, adriamycin
(ADM) resistant sublines from 2 murine solid
tumour lines (EMT6 and RIF-1), it has proved
extremely difficult to obtain such a subline from a
range of human lung cancer cell lines of various
types. We have now, however, isolated an ADM-
resistant subline (LX) of the small cell lung cancer
line NCI-H69 (originally provided by Dr. D.
Carney). The subline LX was obtained by serial
growth in the presence and absence of ADM over a
period of 9 months. The sensitivity to ADM of LX
is much lower than the sensitivity of 14 other
human lung cancer cell lines studied. Subline LX is
also very resistant to colchicine and vincristine but
similar to the parent line in sensitivity to
melphalan, CCNU, bleomycin and aclacinomycin
A. Intracellular ADM concentrations after acute
exposure are reduced in LX cells compared with
the parent cells. Resistance to ADM of LX is lost
only slowly during growth in the absence of the
drug. Continuing studies are concerned with an
examination of membrane glycoproteins in subline
LX and determination of cellular pharmacokinetics
for a range of anthracyclines.
Whole body hyperthermia - effects on the
pharmacokinetics of two nitroimidazole
radiosensitizers SR 2508 and Ro 03-8799 in mice
M.I. Walton, N.M. Bleehen & P. Workman
MRC and University Department ofClinical
Oncology, Hills Road., Cambridge, CB2 2QH, UK.
Whole body hyperthermia (WBH) is currently being
evaluated in combination with chemotherapy,
through there have been very few detailed studies
on the effects of WBH on drug pharmacokinetics.
Nitroimidazole radiosensitizers show enhanced
tumour cytotoxicity and radiosensitization with
heat in vitro, and we have investigated the effects of
WBH in mice on the pharmacokinetics of two
radiosensitizers undergoing clinical trial. These are
SR 2508, a hydrophilic neutral nitroimidazole, and
Ro 03-8799, a basic lipophilic nitroimidazole.
Drugs were given i.v. to C3H mice bearing KHT
tumours, 10min before WBH in an incubator (core
temp, 41 +0.50°C for 45min). Both compounds
were given at 60% heated LD50 dose, i.e.
3mmolkg-1 SR 2508 and 0.69mmolkg-1 Ro 03-
8799. Plasma, tumour and brain drug concen-BACR/RSM ABSTRACTS 601
trations were measured in heated and control mice
using HPLC. Heat increased the acute toxicity of
SR 2508 and Ro 03-8799 5-fold and 3-fold
respectively. WBH significantly prolonged the
terminal half-life (t1) of SR 2508 from 83 +5min to
121 +2min (95% conf, P<0.001). It also increased
Ro 03-8799 t1 by 26% from 23 +2min to
29+2min (95% conf, P<0.001). Plasma clearance
was reduced in heated mice from 1.1 to
0.7mlhr- g-1 for SR 2508 and from 3.89 to
3.19mlh-g-1 for Ro 03-8799. WBH greatly
inhibited glomerular filtration specifically during
the heating period, as measured by Cr" EDTA
clearance. Ro 03-8799 tissue/plasma ratios were
decreased by WBH, e.g. at 60min tumour/plasma
ratios were reduced by 44% from 2.5 to 1.4. WBH
did not alter SR 2508 brain/plasma ratios but
slightly reduced tumour/plasma ratios, e.g. from
1.22 to 1.12 at 2h. In conclusion, WBH profoundly
affects plasma pharmacokinetics and renal
clearance of Ro 03-8799 and particularly SR 2508.
It also reduces Ro 03-8799 tumour/plasma and
brain/plasma ratios at later times.
Induction of differentiation of HL60 leukaemic cells
in vitro by analogues of N-methylformamide and the
relationship with antitumour activity and toxicity
in vivo
S.P. Langdon & J.A. Hickman
CRC Experimental Chemotherapy Group, University
ofAston, Birmingham, UK.
N-Methylformamide (NMF), a polar solvent, is in
phase 2 clinical trial. Dexter et al. have suggested
that its antitumour action might be related to its
ability to induce differentiation in tumour cells
(Cancer Res. (1982) 42, 5018). We have studied the
ability of a series of analogues of NMF to induce
differentiation inHL60promyelocyticcellsin vitroand
have related this to their toxicity and antitumour
activity in vivo. The general formula of these
analogues was R3CONR'R2 where RI=H, Me, Et;
R2=H, Me, and R3=H, Me, NH2 NHMe or
NMe2. Differentiation was assessed by the ability
of cells to phagocytose yeast and reduce nitroblue
tetrazolium. Each of the analogues tested was able
to induce differentiation in vitro over a narrow
concentration range. A simple inverse relationship
appears to exist between the optimal inducing
concentration, the cytotoxic concentration in vitro
and the molecular weight of the compound. This
suggest that the effects of in vitro differentiation
and cytotoxicity may be mediated in a relatively
non-specific manner. In contrast to the in vitro
differentiation results, only NMF was active against
murine tumours in vivo. The methylated acetamides
and ureas were inactive in vivo, despite being less
toxic than NMF and being more potent inducers of
differentiation. While 150mM NMF was required
to induce differentiation in vitro, 7mM is the
maximum plasma concentration that may be
maintained in mice. These results suggest that
unless NMF is metabolized in vivo to a more potent
inducing species, it seems unlikely that its
antitumour action and its ability to induce differen-
tiation are related. Additionally, the methylated
acetamides and ureas appear to be more promising
candidates for the induction of terminal differen-
tiation of human tumour cells in vivo than NMF.
Treatment of two transplantable tumours with the
putative anti-angiogenic combination of heparin plus
cortisone
M. Penhaligon & R.S. Camplejohn
Richard Dimbleby Department ofCancer Research,
St Thomas's Hospital Medical School, London
SE] 7EH, UK.
Folkman et al. (1983) Science, 221, 719 reported
that heparin combined with cortisone caused
regression and complete cure of a number of
transplantable tumour types. Some of these tumour
types, e.g. 3LL and B16, grow rapidly and
metastasize and are not usually curable by
chemotherapy. Folkman's work suggested that
these stimulating results involved an inhibition of
tumour angiogenesis. However, the efficacy of this
therapy was dependent on the source of heparin
and the most potent, Panheparin (Abbott) is no
longer being manufactured. We have made an
initial study of heparins from five different
manufacturers (Weddel, Monparin; Sigma; Leo;
Boots; Organon, Diosynth) differing in source
(pig/cow, lung/intestine) and in degree of purity.
C3H/He mice bearing either C3H mouse mammary
adenocarcinomas or RIF-I fibrosarcomas of
approximately 180mm3 volume were treated with
a combination of heparin (500 anticoagulation
unitsml-1 drinking water) plus cortisone (250mg
kg-'day-1 s.c. tapering to 37mg- day-' or a
constant dose of 75mgkg- day-1) these being
the drug doses and schedules found effective in
Folkman's studies. RIF-1 tumours shrank to
approximately half the volume at the start of
therapy after only 3 days of treatment; mammary
tumours took longer to respond, not reaching half
the starting volume until after 11 days of treatment.
However, response to combined heparin and
cortisone therapy was in fact no different from the
response to cortisone used alone and in both tumour
types the response was transient and tumours
eventually regrew. Also, cortisone treatment was602 BACR/RSM ABSTRACTS
extremely toxic to these animals and expenrments
had to be terminated after about 3 weeks of
therapy. These results differ from those of Folkman
et al. who found no antitumour effect using
cortisone alone and experienced none of the early
toxic effects seen in this study.
Nucleotide "prodrugs" of 6-mercaptopurine and
cytosine arabinoside
D.M. Tidd, H.P. Johnston, P. Hawley, S. White &
I. Gibson
School ofBiological Sciences, University ofEast
Anglia, Norwich, NR4 7TJ, UK.
Using 6-mercaptopurine (MP) as a model system
we have demonstrated that the efficacy of anti-
metabolite nucleotide "prodrugs" designed to
circumvent drug resistance may be limited by their
hydrophilic character and by the degradative ac-
tivity of serum phosphodiesterases. Bis(thioinosine)-
5', 5"'-phosphate [(bisMPR)P], an MP nucleotide
prodrug originally synthesized by Montgomery
et al. (1963 Nature, 199, 769); was cytotoxic to our
thiopurine-resistant L1210/MPR cell line in culture;
however, the extent of its effects was limited by its
intrinsically slow action and its relatively rapid
extracellular degradation. Esterification of the sugar
hydroxyls with butyric acid enhanced the rate of
action of bis(MRP)P and afforded considerable
protection against breakdown by serum enzymes.
Both bis(MRP)P and the lipophilic butyryl
derivative, bis(dibut.MPR)P induced progressive
inhibitions of incorporation of radiolabelled
precursors into cellular RNA, DNA and protein.
Bis(dibut.MPR)P was more cytotoxic than
bis(MPR)P against L1210/MPR cells, and also
against thiopurine-resistant Chinese hamster
CH/TG cells which were equally insensitive to MP
riboside and bis(MPR)P itself. The properties of the
MP derivatives were compared with those of
analogous compounds of cytosine arabinoside.
Cerebral photosensitization by haematoporphyrin
derivative (HPD)
M.C. Berenbauml, G.W. Hall' & A.D. Hoyes2
1Department ofExperimental Pathology,
2Department ofAnatomy, St Mary's Hospital
Medical School, London, W2 JPG, UK.
Photodynamic therapy (systemic administration of
tumour-localising porphyrin followed by exposure
of the tumour to light) may be a useful treatment
for malignant brain tumours as (i) porphyrins are
excluded from most of the brain by the blood-brain
barrier (BBB) but not from tumours, (ii) the brain
is relatively translucent to light of the appropriate
wave-lengths, (iii) brain tumours rarely metastasize
and so, in principle, the whole tumour can be
illuminated, (iv) the results of other treatments are
poor.
However, we find that injection of HPD in
rodents produces a long-lasting (>3 months)
photosensitization of normal brain, exposure of the
cranium to light causing a rapid and usually fatal
cerebral oedema. Surviving animals show necrosis
of illuminated areas of brain. The possibilities are
either (i) HPD, contrary to current belief, does pass
the BBB or (ii) HPD is retained for a remarkably
long time on the vascular side of the BBB. Our
evidence suggests the latter, viz (i) the oedema is of
vasogenic origin, (ii) the brain is immediately
sensitized by an injection of protein-bound HPD,
(iii) conventional histology shows early endothelial
cell necrosis, (iv) electron microscopy shows
opening of endothelial tight junctions. These
findings may be relevant to the mechanisms by
which photodynamic therapy damages tumours.
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